The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds
Open accessAbstract
More than 40% of compounds identified through combinatorial screening programs are poorly soluble in water. These molecules are difficult to formulate using conventional approaches and are associated with innumerable formulation-related performance issues. Formulating these compounds as pure drug nanoparticles is one of the newer drug-delivery strategies applied to this class of molecules. Nanoparticle dispersions are stable and have a mean diameter of less than 1 micron. The formulations consist of water, drug, and one or more generally regarded as safe excipients. These liquid dispersions exhibit an acceptable shelf-life and can be postprocessed into various types of solid dosage forms. Drug nanoparticles have been shown to improve bioavailability and enhance drug exposure for oral and parenteral dosage forms. Suitable formulations for the most commonly used routes of administration can be identified with milligram quantities of drug substance, providing the discovery scientist with an alternate avenue for screening and identifying superior analogs. For the toxicologist, the approach provides a means for dose escalation using a formulation that is commercially viable. In the past few years, formulating poorly water-soluble compounds using a nanoparticulate approach has evolved from a conception to a realization whose versatility and applicability are just beginning to be realized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,734
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Studien über die Bildung und Umwandlung fester Körper: 1. Abhandlung: Übersättigung und Überkaltung
Ostwald, W. (1897) · Zeitschrift für Physikalische Chemie · doi:10.1515/zpch-1897-2233 · Cited by 2,103
THE RATE OF SOLUTION OF SOLID SUBSTANCES IN THEIR OWN SOLUTIONS.
Noyes, A. A., & Whitney, W. R. (1897) · Journal of the American Chemical Society · doi:10.1021/ja02086a003 · Cited by 1,884
Pharmacokinetics of Pegylated Liposomal Doxorubicin: Review of Animal and Human Studies
Gabizon, A., Shmeeda, H., & Barenholz, Y. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00002 · Cited by 1,634
Nanosuspensions in drug delivery
Rabinow, B. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1494 · Cited by 1,524
Remington: The science and practice of pharmacy
(1996) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(96)90065-6 · Cited by 1,433
Nanosuspensions as particulate drug formulations in therapy
Müller, R. H., Jacobs, C., & Kayser, O. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00118-6 · Cited by 1,370
Nanosizing: a formulation approach for poorly-water-soluble compounds
Merisko-Liversidge, E., Liversidge, G. G., & Cooper, E. R. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00251-8 · Cited by 1,263
Self-citationPouton, C. W. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00167-6 · Cited by 1,230
Letchford, K., & Burt, H. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.11.009 · Cited by 1,143
Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation
KECK, C., & MULLER, R. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.05.009 · Cited by 1,061
Singh, R., Pantarotto, D., Lacerda, L., Pastorin, G., Klumpp, C., Prato, M., Bianco, A., & Kostarelos, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509009103 · Cited by 1,043
Organic Nanoparticles in the Aqueous Phase—Theory, Experiment, and Use
Horn, D., & Rieger, J. (2001) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20011203)40:23<4330::aid-anie4330>3.0.co;2-w · Cited by 1,015
Hörter, D., & Dressman, J. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00130-7 · Cited by 819
Liversidge, G. G., & Cundy, K. C. (1995) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(95)00122-y · Cited by 739
Self-citationJinno, J.-I., Kamada, N., Miyake, M., Yamada, K., Mukai, T., Odomi, M., Toguchi, H., Liversidge, G. G., Higaki, K., & Kimura, T. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.11.013 · Cited by 510
Self-citationNanosuspensions for the Formulation of Poorly Soluble Drugs
Müller, R., Jacobs, C., & Kayser, O. (2000) · Drugs and the Pharmaceutical Sciences · doi:10.1201/b14005-13 · Cited by 501
Crystallization mechanisms in solution
Boistelle, R., & Astier, J. P. (1988) · Journal of Crystal Growth · doi:10.1016/0022-0248(88)90294-1 · Cited by 483
Ranade, V. V., Hollinger, M. A., & Cannon, J. B. (2003) · CRC Press eBooks · doi:10.1201/9781420040142 · Cited by 456
Designing dendrimers for drug delivery
Liu, M., & Fréchet, J. M. J. (1999) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(99)00203-5 · Cited by 434
Microemulsion formulation for enhanced absorption of poorly soluble drugs
Kawakami, K., Yoshikawa, T., Moroto, Y., Kanaoka, E., Takahashi, K., Nishihara, Y., & Masuda, K. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00049-4 · Cited by 306
Wu, Y., Loper, A., Landis, E., Hettrick, L., Novak, L., Lynn, K., Chen, C., Thompson, K., Higgins, R., Batra, U., et al. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.08.001 · Cited by 275
Ilium, L., Davis, S. S., Wilson, C. G., Thomas, N. W., Frier, M., & Hardy, J. G. (1982) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(82)90113-2 · Cited by 253
Nanoparticles for Drug Delivery
(2021) · Gels Horizons: From Science to Smart Materials · doi:10.1007/978-981-16-2119-2 · Cited by 203
Site–Specific (Targeted) Drug Delivery in Cancer Therapy
Poste, G., & Kirsh, R. (1983) · Bio/Technology · doi:10.1038/nbt1283-869 · Cited by 166
Juliano, R. L. (1988) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(88)90004-x · Cited by 142
Influence of high pressure homogenisation equipment on nanodispersions characteristics
Liedtke, S., Wissing, S. A., Müller, R. H., & Mäder, K. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00417-2 · Cited by 140
Jani, P. U., Florence, A. T., & McCarthy, D. E. (1992) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(92)90162-u · Cited by 136
Chapter 4 Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells
Poste, G. H., Papahadjopoulos, D., & Vail, W. J. (1976) · Methods in cell biology · doi:10.1016/s0091-679x(08)60468-9 · Cited by 133
Langguth, P., Hanafy, A., Frenzel, D., Grenier, P., Nhamias, A., Ohlig, T., Vergnault, G., & Spahn-Langguth, H. (2005) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-52182 · Cited by 98
Hillery, A. M., & Florence, A. T. (1996) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(95)04353-5 · Cited by 81 · cited 2×
“…there are some reports that uptake of nanoparticulate materials can be mediated by various cellular or paracellular processes (Jani et al., 1992; Hillery and Florence, 1996), improving absorption remains the primary means for increasing the bioavailability of a poorly water-soluble compound…”
BackgroundMouton, J. W., Peer, A. V., Beule, K. D., van Vliet, A., Donnelly, J. P., & Soons, P. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00630-06 · Cited by 78
Site-Specific Drug Delivery in the Gastrointestinal Tract
Wilding, I. R. (2000) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v17.i6.10 · Cited by 74
Insulin Nanoparticles: A Novel Formulation Approach for Poorly Water Soluble Zn-Insulin
Merisko-Liversidge, E. M., McGurk, S. L., & Liversidge, G. G. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000041446.14569.e2 · Cited by 71
Self-citationThe Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers
Kraft, W. K., Steiger, B. W., Beussink, D., Quiring, J. N., Fitzgerald, N., Greenberg, H. E., & Waldman, S. A. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003261490 · Cited by 62
Wolf, G. L., Gazelle, G. S., McIntire, G. L., Bacon, E. R., Toner, J. L., Cooper, E. R., & Haley, P. J. (1994) · Academic Radiology · doi:10.1016/s1076-6332(12)80008-0 · Cited by 28
Cited by
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Sol–gel based materials for biomedical applications
Owens, G. J., Singh, R. K., Foroutan, F., Alqaysi, M., Han, C.-M., Mahapatra, C., Kim, H.-W., & Knowles, J. C. (2016) · Progress in Materials Science · doi:10.1016/j.pmatsci.2015.12.001 · Cited by 958
Advances in Oral Drug Delivery
Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., & Ahmad, M. Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.618411 · Cited by 876
Shegokar, R., & Müller, R. H. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.07.044 · Cited by 740
Mesoporous silica nanoparticles in medicine—Recent advances
Mamaeva, V., Sahlgren, C., & Lindén, M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.018 · Cited by 707
Metadata
- Authors
- Merisko-Liversidge, E. M., & Liversidge, G. G.
- Venue
- Toxicologic Pathology
- Publisher
- SAGE Publications
- Published
- 2008-01
- Volume
- 36
- Issue
- 1
- Pages
- 43-48
- ISSN
- 0192-6233 (ISSN-L)
- 1533-1601
- OpenAlex
- W2132081026
- Cited by
- 579
- References
- 37
- FWCI
- 12.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.